To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News | Article
Timo van Kerkoerle, researcher at NeuroSpin, is one of the 408 winners of the prestigious ERC Starting Grant 2022 call of the European Research Council. Another European success for the Institute.
The QSM4SENIOR project, led by NeuroSpin and the company VENTIO, aims at developing an original early biomarker of aging by using data from the SENIOR study of NeuroSpin. QSM4SENIOR has just been funded by the EOSC-Life.
Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.
A project at the interface between quantum chemistry and molecular dynamics for the study of complex molecular assemblies, led by Michel Masella (Joliot) and Luigi Genovese (IRIG), makes it possible, for applications in biology/health, to take full advantage of the new supercomputers of the Public Procurement of Innovations for High-Performance Computing (PPI4HPC, H2020) project hosted at the Très Grand Centre de Calcul (TGCC) of the CEA-Bruyères-le-Châtel.
The members of the Organic Chemistry Division (DCO) of the French Chemical Society met on Monday 10 May to award the DCO 2021 prizes. Sophie Feuillastre and Davide Audisio, both researchers at the SCBM (CEA-Joliot Department of Medicines and Technology for Health) are among the lucky winners.
Aloïse Mabondzo, research director, head of the Neurovascular Pharmacology Group of the SPI (DMTS), co-founder and scientific director (CSO) of CERES BRAIN THERAPEUTICS, has just obtained funding of nearly one million US dollars from the prestigious National Institute of Health for his project « Neuroprotective Strategy: Novel Purine Derivatives for Neonatal Hypoxia-ischemia ».
Jean-Luc Gennisson (BioMaps/SHFJ) coordinated, in partnership with the CEA-List (Sylvain Chatillon), the EchoBrain project (ATTRACT/H2020) aimed at adapting the digital tools developed by the List (CIVA platform) to significantly increase the quality of brain echography images, simple alternative compared to the methods (MRI, X-ray scanner) currently used for the diagnosis of strokes.
Coordinated by the Imagine Institute for Genetic Diseases, the ATRACTion program is based on a consortium of 11 academic and industrial partners, including SPI (DMTS), and aims to develop a precision medicine for patients with autoimmune and inflammatory diseases associated with primary immune deficiencies.
AROMA, a FET-Open H2020 project, aims to develop the methodology necessary for the optimal operation of the future 11.7 T MRI being installed at NeuroSpin. This 5-year project, coordinated by Nicolas Boulant (NeuroSpin), with an overall budget of 3.6 million euros, involving six partners from five countries representing academia and industry, started on January 1, 2021.
EBRAINS (European Brain ReseArch INfrastructureS) is a european research infrastructure designed by the scientific community which, based on a set of state-of-the-art digital platforms, aims to answer the analysis and processing needs of large brain data sets. CEA carries for France EBRAINS inscription on the European Strategy Forum on Research Infrastructures roadmap, which was submitted in early September 2020.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.